Stay informed on the latest biotech developments by signing up for the newsletter. In the latest edition, Bristol Myers Squibb reported positive results for Sotyktu in treating psoriatic arthritis. Novo Nordisk’s obesity drug, CagriSema, fell short of weight loss projections, impacting the company’s stock value. The FDA granted breakthrough status to medical devices like Neuralink’s brain implant and Field Medical’s technology for heart arrhythmias. Vertex’s Alyftrek was approved for cystic fibrosis, while Eli Lilly’s Zepbound received approval for sleep apnea. These developments have implications for the market and patient care. Additional news covers GSK’s cancer drug and Galectin’s trial results.
Source link
Vertex, Neuralink, Bristol, Zepbound news
